ExoProTher – Investor Forum at the World Stem Cell Summit

ExoProTher Co-Founder and CEO Dr. Lana Volokh delivers a formal corporate overview, followed by a Q & A session moderated by a Noble Capital Markets equity research representative.

ExoProTher Medical is a preclinical stage company developing a first in class oncology therapeutic platform targeting cancers with mutation in gene TP53 – the most frequently observed genetic alterations in human cancer.